论文部分内容阅读
目前治疗阻塞性睡眠呼吸暂停(OSA)选用连续正压气道通气(CPAP),对此并非所有患者都能耐受。现对8例OSA的男患者给予盐酸可乐宁(一种具有遏止REM活性的α_2—肾上腺素激动剂),并评价其效果。方法随机指定患者参加两个治疗组(即一组先给安慰剂,再给可乐宁,另一组先给可乐宁,再给安慰剂)。可乐宁治疗期,就寝时给予口服可乐宁0.2mg共10日,安慰剂应用期亦为10日,两期之间(间隔一周)不给予安慰剂或可乐宁。两个治疗组开始前作了对照研究,并进行多导睡眠描记。对每例患者都做了可乐宁治疗期、安慰剂应用期和对照组两整夜睡眠分期和呼吸类型的对比研究。
The current treatment of obstructive sleep apnea (OSA) use continuous positive airway pressure (CPAP), which is not tolerable in all patients. 8 male patients with OSA are now given clonidine hydrochloride (an α 2 -adrenoceptor with a repressor of REM activity) and the effect is evaluated. Methods Patients were randomly assigned to two treatment groups (one for placebo followed by one for clonidine and the other for placebo). Clonidine treatment period, at bedtime given oral clonidine 0.2mg a total of 10 days, placebo application period of 10 days, two periods (one week interval) is not given placebo or clonidine. The two treatment groups before the start of a controlled study, and polysomnography. For each patient, a comparative study of clonidine treatment, placebo application and two overnight sleep stages and respiration type in the control group was performed.